Prelude Therapeutics Business Summary

Prelude Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of highly selective, small-molecule precision oncology therapies. The company’s business model has transitioned from a pure-play research entity to a collaboration-driven revenue model, notably marked by a late-2025 strategic partnership with Incyte for its JAK2V617F program, which provides upfront capital, equity investment, and milestone-based payments. Its primary business segments are centered on targeted protein degradation and mutant-selective inhibition; as of early 2026, the company has prioritized its KAT6A selective degrader for ER+ breast cancer and the PRT12396 JAK2 inhibitor while pausing its SMARCA2 degrader program to optimize resources. In the competitive landscape, Prelude operates alongside precision medicine firms such as Relay Therapeutics, Revolution Medicines, and Arvinas, positioning itself as a specialist in overcoming resistance mechanisms through superior molecular selectivity and its proprietary "Discovery Engine." The company was founded in 2016 by CEO Krishna (Kris) Vaddi, Ph.D., a founding scientist at Incyte who played a critical role in the development of the blockbuster oncology drug Jakafi. The leadership team is characterized by a deep "Incyte pedigree," including Chief Scientific Officer Peggy Scherle, Ph.D., and Chief Chemistry Officer Andrew Combs, Ph.D., both of whom led major discovery efforts at Incyte for over a decade. The executive suite is further bolstered by Chief Business Officer Sean Brusky, an alumnus of Genentech and Roche, and CFO/CLO Bryant Lim. Prelude’s strategic growth is supported by a board and investor base featuring prominent institutional backers such as OrbiMed Advisors, Baker Brothers Investments, and Fidelity Management & Research, with the board chaired by industry veteran Paul A. Friedman, M.D.